Industry Portals
Chemical Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Young & Partners 2025 Pharmaceutical Executive Summit: Fireside Chat with Dr. William Pao, author of “Breakthrough: The Quest for Life-Changing Medicines
William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer
Young & Partners 2025 Pharmaceutical Executive Summit: Doug Long The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, Industry Relations, IQVIA
Young & Partners 2025 Pharmaceutical Executive Summit: Najat Khan Latest Developments in Artificial Intelligence
Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals, Former Chief Data Science Officer & Global Head, Strategy & Portfolio Organization, Innovative Medicine R&D, Johnson & Johnson
Young & Partners 2025 Pharmaceutical Executive Summit: Michael Christel, Fred Hassan Commercialization: Why are Success Rates Falling?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Fred Hassan, Director, Warburg Pincus, Former CEO of Schering Plough and Former CEO of Pharmacia
Young & Partners 2025 Pharmaceutical Executive Summit: William Pao, Paul Sekhri The Changing Roles and Relationships – Biotech and Pharma
William Pao, CEO, Revelio Therapeutics, Inc., Former Head of R&D, Pfizer Paul Sekhri, President and CEO, vTv Therapeutics
Navigating Divergent Currents – Biopharma Review and Outlook (Pharmaceutical Executive, August 2025)
Young & Partners shares proprietary analysis of the M&A, stock market, and funding environment in Biotech and Pharma and the outlook for 2025.
Young & Partners Forum Series: The Energy Transition and its Implications- Jason Bordoff of Columbia University SIPA
Jason Bordoff, Founding Director of the Center on Global Energy Policy, Columbia University SIPA; Previously Special Assistant to President Barack Obama and Senior Director for Energy and Climate Change, the Staff of the National Security Council Peter Young, President and CEO, Young & Partners
The Chemical M&A Market Treads Water (August 12, 2025)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Chemical M&A market in the first half of 2025 and the outlook.
Pharma and Biotech: M&A Review and Outlook
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma M&A market in the first half of 2025 and the outlook.
Peter Young Receives the Foreign Policy Association Medal
Peter Young, Chief Executive Officer of Young & Partners was awarded the Foreign Policy Association Medal Award at a dinner held at the Harvard Club of New York on June 26. Past recipients include the Honorable Michael Bloomberg, Mayor, New York City; Timothy Geithner, Chairman, Federal Reserve Bank of New York; Jean-Claude Trichet, President of the European Central Bank; Kevin Rudd, Prime Minister, Australia; Sheila C. Bair, Chairman, Federal Deposit Insurance Corporation, and Anne-Marie Slaughter, Dean, Woodrow Wilson School of Public and International Affairs, Princeton University, among others.
Chemical Stock Market and Funding in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis and outlook of Chemical stock market and funding market in the first quarter of 2025 and the outlook for the rest of 2025.
Biotech and Pharma Stock Market and Funding in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma Stock Market and Funding in the first quarter of 2025 and the outlook.
Chemical M&A in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis and outlook of Chemical M&A in the first quarter of 2025 and the outlook for the M&A market in the rest of 2025.
Biotech and Pharma M&A in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma M&A market in the first quarter of 2025 and the outlook.
Chemical Executives Deal with Tariffs (ICIS Chemical Business May 9 – May 15, 2025)
ICIS Chemical Business reports on panel discussion (Apollo, Dow and Westlake executives) moderated by Peter Young on April 30, 2025.
Young & Partners Forum Series: How to Build an Effective Salesforce – Adam Woodrow of Paratek Pharmaceuticals
Adam Woodrow, President and Chief Commercial Officer, Paratek Pharmaceuticals Peter Young, President and CEO, Young & Partners
Young & Partners Forum Series: Drug Innovation Insights – Lessons From History – William Pao of Revelio Therapeutics
William Pao, CEO of Revelio Therapeutics and Former Chief Development Officer and Executive Vice President for Pfizer Peter Young, President and CEO, Young & Partners